---
title: "FDA approves first targeted pancreatic cancer drug; Trump administration strikes biotech drug-pric"
id: "stat-news-2-stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "STAT News"
source_url: "https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/?utm_campaign=rss"
published_at: "2026-08-27T13:20:27.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# FDA approves first targeted pancreatic cancer drug; Trump administration strikes biotech drug-pric
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-2-stat-pharmalittle-we-re-reading-about-a-pancreatic-cancer-drug-approval-a-trump
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/?utm_campaign=rss)
- **Published At:** 2026-08-27T13:20:27.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- The U.S. Food and Drug Administration approved a new treatment from Revolution Medicines that targets a genetic driver of **pancreatic cancer**, described as the first therapy to attack that genetic cause for the disease. - The approval was supported by a trial in which patients receiving the drug as a second-line therapy had a median **overall survival** of 13.2 months versus 6.7 months for patients receiving standard chemotherapy. - The approval is positioned as potentially practice-changing for advanced pancreatic cancer, an aggressive and highly lethal malignancy. - The Trump administration plans to announce a round of **drug-pricing** agreements with several midsized biotech companies under which participating companies would offer discounts on outpatient drugs to state Medicaid programs, aligning state-paid prices with those charged in foreign countries. - Participation by state Medicaid programs in the new biotech agreements would be optional; in return, companies would receive exemptions from pilot programs requiring similar discounts in Medicare. Discussions also include potential tariff relief for some companies. - The article notes a U.S. appeals court rejection of PhRMA’s challenge to the Medicare drug price negotiation program in a section header, though detailed facts of that ruling were not reported in the source excerpt. - Portions of the original STAT piece are exclusive to STAT+ subscribers; additional details in the original report were behind the STAT+ paywall and are not reported in the provided source text.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-white.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/?utm_campaign=rss) [Hospitals](https://www.statnews.com/category/hospitals/) [Mental Health](https://www.statnews.com/topic/mental-health/) [education](https://www.statnews.com/topic/education/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) Reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)Newsletter[Pharmalot](https://www.statnews.com/category/pharma/pharmalot/) # Pharmalittle: We’re reading about a pancreatic cancer drug approval, a Trump deal with biotechs, and more ## U.S. appeals court rejects PhRMA challenge to the Medicare drug price negotiation program * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/pharmalot/2026/08/27/pancreatic-cancer-drug-approved-trump-deal-with-biotechs/?utm_campaign=rss) ![an anthropomorphized red and blue pill illustrated in the style of the famous american gothic painting](https://www.statnews.com/wp-content/uploads/2015/11/PHARMALOT_LITTLE-copy-645x645.jpg) Alex Hogan/STAT ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Aug. 27, 2026 Pharmalot Columnist, Senior Writer ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") 2. [](https://x.com/Pharmalot "X") ed.silverman@statnews.com Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the soggy weather hovering over the Pharmalot campus right now, because our spirits remain sunny, nonetheless. Why? We will trot out a bit of insight from the Morning Mayor, who would say “Every new day should be unwrapped like a precious gift.” To celebrate the notion, we are brewing still more cups of stimulation and invite you to join us. Our choice today is the mysterious witch’s brew. Meanwhile, here are a few items of interest. Hope you have a smashing day and, of course, do stay in touch. … **The U.S. Food and Drug Administration approved a life-extending treatment for advanced pancreatic cancer made by Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy,** [STAT](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) says. The approval was supported by a practice-changing clinical trial showing patients with advanced pancreatic cancer who received the drug as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients given standard chemotherapy. Advertisement **The Trump administration plans to announce a new round of drug-pricing agreements with several midsized biotech companies on Monday** , [Bloomberg News](https://www.bloomberg.com/news/articles/2026-08-26/white-house-to-announce-new-drug-pricing-deals-with-biotechs) reports. The companies will agree to provide discounts on outpatient drugs to state Medicaid programs so that the prices states pay align with what the companies charge in foreign countries. Participation by state Medicaid programs is optional. In exchange, the companies will be exempt from pilot programs forcing similar discounts in Medicare. Relief from tariffs is also part of some of the discussions. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [pharmalittle](https://www.statnews.com/topic/pharmalittle/), [STAT+](https://www.statnews.com/topic/stat-plus/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2021/02/ed-s-avatar-small4-80x80.png) [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Pharmalot Columnist, Senior Writer 1. [](https://x.com/Pharmalot "X") 2. 3. [](https://www.linkedin.com/in/edsilverman/ "Linkedin") Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning [Pharmalittle newsletter](https://www.statnews.com/signup/pharmalittle/) and the afternoon [Pharmalot newsletter](https://www.statnews.com/signup/pharmalot/). ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_180917809-80x80.jpeg) [Nurse practitioner trainees find themselves stymied by shortage of clinical mentors](https://www.statnews.com/2026/08/24/nurse-practitioner-preceptor-shortage-clinical-placement-challenges/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/daniel-80x80.jpg) [Hospitals are plotting a long-shot push to roll back $1 trillion in Medicaid cuts](https://www.statnews.com/2026/08/27/hospitals-lobby-reverse-medicaid-cuts-part-2-unraveled-series/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/08/AdobeStock_998225050-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [The mystery of Moderna’s magic algorithm](https://www.statnews.com/2026/08/27/moderna-merck-cancer-vaccine-secret-ingredient-an-algorithm/) 4. ![](https://www.statnews.com/wp-content/uploads/2024/08/IMG_4258-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Alnylam’s heart drug troubles take center stage at a cardiology conference](https://www.statnews.com/2026/08/27/alnylam-amvuttra-nucresiran-heart-drugs-esc/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/Bolner01-80x80.jpg) [A state gave sheriffs 20% of its opioid settlement cash. We followed the money](https://www.statnews.com/2026/08/27/opioid-settlement-funds-enforcement-or-treatment-louisiana-sheriff-investigation/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2026/08/2026_CancerReport_ReportCover-328x424.jpg) Explore Cancer’s transformational moments: KRAS, CAR-T, immunotherapy, and more ](https://reports.statnews.com/products/cancer-transformational-moments-advances-in-kras-car-t-immunotherapy) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/924_Samsung_VirtualEvent_Wordpress_FeaturedImage-80x80.jpg) Biosimilars: Have We Reached an Inflection Point? Virtual Sep 24 ](https://www.statnews.com/event/biosimilars-what-is-next-virtual-event-sept-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/01/Flagship2026_Wordpress_CalendarImageRegGoLive-1-80x80.jpg) 2026 STAT Summit Boston, MA Oct 14 ](https://www.statnews.com/event/2026-stat-summit/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/08/image-15-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Inside Moderna and Merck’s cancer vaccine triumph](https://www.statnews.com/2026/08/24/inside-moderna-and-merck-cancer-vaccine-triumph/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/08/Revmed_campus2-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA approves new pancreatic cancer drug expected to usher in new era of treatment](https://www.statnews.com/2026/08/26/pancreatic-cancer-drug-rasonque-approved/) 3. ![](https://www.statnews.com/wp-content/uploads/2020/02/AdobeStock_284333299-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial](https://www.statnews.com/2026/08/19/mrna-cancer-vaccine-trial-melanoma-merck-moderna/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/08/AP26111614763455-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [HHS document offers new clues to Kennedy’s vaccine plans](https://www.statnews.com/2026/08/21/rfi-reveals-possible-kennedy-strategy-vaccine-policy-changes/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/08/GettyImages-2270934863-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Comments on OMB research rule mysteriously removed from federal website](https://www.statnews.com/2026/08/25/russell-vought-omb-funding-comments-daughter-benefited-nih-research/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 26, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about a GSK shingles shot, U.S. employers dropping GLP-1 coverage, and more ](https://www.statnews.com/pharmalot/2026/08/26/gsk-shingles-shot-us-employers-dropping-glp1-coverage/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 25, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Turkish antitrust authorities probe Teva for allegedly gaming the patent system, disparaging rival drugs ](https://www.statnews.com/pharmalot/2026/08/25/turkish-authorities-probe-teva-gaming-patent-system-disparaging-rivals/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 25, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about RFK Jr. vaccine disclosures, a Merck loss over Medicare prices, and more ](https://www.statnews.com/pharmalot/2026/08/25/rfk-vaccine-disclosure-merck-court-loss-over-medicare/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 24, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more ](https://www.statnews.com/pharmalot/2026/08/24/state-medicaid-obesity-drugs-regenxbio-gene-therapy/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Pharmalot Pharmalot August 21, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Up and down the ladder: The latest comings and goings ](https://www.statnews.com/pharmalot/2026/08/21/up-down-ladder-latest-comings-goings-jobs-2/) By [Ed Silverman](https://www.statnews.com/staff/ed-silverman/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-c
## Related Clinical Research

- [Moderna–Merck cancer vaccine and the role of the algorithm behind its mRNA design](https://medichelpline.com/clinical-feed/stat-news-1-stat-the-mystery-of-moderna-s-magic-algorithm.md)
- [FDA approves Rasonque (daraxonrasib) for advanced pancreatic cancer after survival benefit](https://medichelpline.com/clinical-feed/stat-news-1-stat-fda-approves-new-pancreatic-cancer-drug-expected-to-usher-in-new-era-of.md)
- [Personalized mRNA vaccine plus pembrolizumab lowers melanoma recurrence in phase 3 trial](https://medichelpline.com/clinical-feed/medical-news-today-0-novel-mrna-vaccine-plus-immunotherapy-reduces-melanoma-relapse-in-phase-3-trial.md)
- [Link Between Daily Sugary Drink Consumption and Increased Stomach Cancer Risk](https://medichelpline.com/clinical-feed/medical-news-today-1-daily-sugary-drink-consumption-linked-to-more-than-double-stomach-cancer-risk.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.